Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 10, 2026

Back to today

From X

@StableBread

Fajasy on X

If ur reading a write-up and they don't include a valuation range, more often than not: 1) They're lying to themselves. E.g. only pitching bull case. "The next 10x." $GRAB a couple years ago. 2) They're lying to you, the reader. E.g. not focusing on bear case enough. "It's asymmetric"... but actual downside if couple thing flops is 60%+. $FLNC just 2-3 months ago. 3) They have no clue and prob conclude by saying "position as small speculative bet" to be in a win-win scenario to gain subs. $CCXI today... Multiple based valuation is the simple/lazy route and easier to defend, yet less practical. Absolute valuations like DCF or Penman REV forces you to think more through scenarios and the business itself, which is what's actually useful because it's more subjective.
@ACapitalLP 1 click

A Capital on X

I have a theory that a company’s name can sometimes hurt more than help. Forget the obvious dotcom, blockchain and AI naming frenzies. I think there’s a more subtle phenomenon where companies disproportionately sell off because their names are more closely associated with whatever sector or risk the market is trying to avoid, regardless of actual underlying exposure. Look at $PCG vs. $EIX during the LA wildfires. $PCG had less direct exposure but traded at a larger discount. Everyone associates PG&E with bankruptcy, lawsuits and wildfires (thank you, Erin Brockovich). What the hell is Edison International, a light bulb company? Even more subtle: FedEx Freight ($FDXF) vs. $SAIA. One screams trucking and economic cyclicality. The other sounds like a beauty brand. Sometimes the name itself becomes a risk factor…

Investor Letters

All letters

Golar LNG q2’26 Operational Update

Golar LNG ordered a $2.45 billion fourth FLNG vessel, targeting 3.5MTPA of capacity and $400 million in annual EBITDA under a 20-year…

GLNG $4.9B
Monte Independent Investment Research

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $515M
Stock Thoughts 2 clicks
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $314M
Value Investors Club

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

SLDP $528M
Quad 7 Capital 2 clicks

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.